We bring you the latest news from the healthcare about the health care in the United Kingdom.

zondag 4 november 2018

The Lancet: [Articles] Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE):...

[Articles] Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
Radiotherapy to the prostate did not improve overall survival for unselected patients with newly diagnosed metastatic prostate cancer.
Read more

[Comment] Radiotherapy for newly diagnosed oligometastatic prostate cancer
The standard of care for metastatic prostate cancer is systemic therapy in the form of androgen deprivation therapy with or without novel antiandrogens or chemotherapy.1 Administering local treatment to the primary tumour in the setting of metastatic prostate cancer has long been postulated to have a survival benefit on the basis of retrospective series.2–7 But such series can have selection bias in that patients undergoing local treatment can also have a low volume of metastatic disease (oligometastases), creating a major confounder in most analyses.
Read more

[Comment] The extending scope of kinase inhibition in immune diseases
Functional mutation analyses in patients with immune deficiencies identified Janus kinases (JAKs) as plausible regulators of the immune response. Thereafter, elegant signalling biology generated a compelling rationale for the use of small molecule inhibitors to recapitulate the cytokine blocking activities of biologics. JAK inhibitors have thus emerged as novel immune modifiers that target cytokines via blockade of intracellular cytokine receptor signalling pathways. Four members of the family (JAK1, JAK2, JAK3, and TYK2) can form a variety of heterodimers (eg, JAK1/JAK2 and JAK1/JAK3) and transmit signals from the cell membrane to the nucleus (via cytosolic shuttling proteins) to activate leucocytes and stromal cells and drive inflammation.
Read more

[Articles] Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial
Filgotinib is efficacious and safe for the treatment of patients with active ankylosing spondylitis who have not responded to first-line pharmacological therapy with NSAIDs. Further investigation of filgotinib for ankylosing spondylitis is warranted.
Read more

[Articles] Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
Filgotinib is efficacious for the treatment of active psoriatic arthritis, and no new safety signals were identified.
Read more